Anixa Biosciences director Lewis Titterton buys $6,020 price of inventory

SAN JOSE, Calif.— Lewis (JO:LEWJ) H. Titterton Jr., a director at Anixa Biosciences Inc. (NASDAQ:ANIX), has elevated his stake within the firm with a current buy of frequent inventory. Based on a submitting with the Securities and Trade Fee, Titterton acquired 2,000 shares on January 22, 2025, at a worth of $3.01 per share. This transaction quantities to a complete funding of $6,020. The acquisition comes because the inventory has proven sturdy momentum, with a 15.31% return over the previous week, in accordance with InvestingPro information.

Following this acquisition, Titterton now holds 930,334 shares of Anixa Biosciences. The acquisition displays the director’s ongoing confidence within the firm, which is engaged within the growth of pharmaceutical preparations. Anixa Biosciences, headquartered in San Jose, California, maintains a robust monetary place with a present ratio of 8.54 and minimal debt. Analysts have set worth targets starting from $7 to $10, suggesting potential upside. For deeper insights into ANIX’s monetary well being and extra InvestingPro Suggestions, subscribers can entry the complete evaluation on the platform.

In different current information, Anixa Biosciences has reported encouraging developments in its most cancers analysis packages. The corporate has proven promising preliminary information from its breast most cancers vaccine trial, with over 70% of members displaying immune responses. A Section 2 examine is deliberate to begin in 2025. Anixa’s CAR-T remedy for ovarian most cancers has additionally proven potential, notably in a affected person who stays effectively over 21 months after therapy. The remedy is being examined in additional dose cohorts, with outcomes anticipated to be shared within the coming yr.

Anixa Biosciences ended the 2024 fiscal yr with $20 million in money and investments, offering over 2.5 years of money runway. The corporate has additionally diversified its treasury reserve property with a Bitcoin acquisition, aiming to create long-term worth for its shareholders. Analysts from EF Hutton and H.C. Wainwright have initiated and maintained a Purchase ranking for Anixa Biosciences, regardless of H.C. Wainwright decreasing the 12-month worth goal to $7.00.

These current developments spotlight Anixa Biosciences’ dedication to growing transformative therapies for most cancers and its sturdy place within the monetary and medical arenas.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.